CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
- 7 May 2003
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 59 (3) , 221-225
Abstract
This study analyzed the frequency of CYP2C9 variant alleles and evaluated the impact of CYP2C9 genotype on diclofenac metabolism in a Spanish population.Keywords
This publication has 27 references indexed in Scilit:
- Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotypeClinical Pharmacology & Therapeutics, 2002
- The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitroEuropean Journal of Clinical Pharmacology, 2001
- Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African populationBritish Journal of Clinical Pharmacology, 2001
- Is diclofenac a valuable CYP2C9 probe in humans?European Journal of Clinical Pharmacology, 2001
- Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele.European Journal of Clinical Pharmacology, 2000
- Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish PopulationBiochemical and Biophysical Research Communications, 1999
- Clinical Pharmacokinetics of DiclofenacClinical Pharmacokinetics, 1997
- Allelic and functional variability of cytochrome P4502C9Pharmacogenetics, 1997
- The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphismPharmacogenetics, 1996
- Detection of CYP2C9 polymorphism based on the polymerase chain reaction in ChinesePharmacogenetics, 1995